178 related articles for article (PubMed ID: 34067671)
1. Anti-Vascular Endothelial Growth Factor C Antibodies Efficiently Inhibit the Growth of Experimental Clear Cell Renal Cell Carcinomas.
Dumond A; Montemagno C; Vial V; Grépin R; Pagès G
Cells; 2021 May; 10(5):. PubMed ID: 34067671
[TBL] [Abstract][Full Text] [Related]
2. Vascular endothelial growth factor C disrupts the endothelial lymphatic barrier to promote colorectal cancer invasion.
Tacconi C; Correale C; Gandelli A; Spinelli A; Dejana E; D'Alessio S; Danese S
Gastroenterology; 2015 Jun; 148(7):1438-51.e8. PubMed ID: 25754161
[TBL] [Abstract][Full Text] [Related]
3. Targeting the pro-angiogenic forms of VEGF or inhibiting their expression as anti-cancer strategies.
Guyot M; Hilmi C; Ambrosetti D; Merlano M; Lo Nigro C; Durivault J; Grépin R; Pagès G
Oncotarget; 2017 Feb; 8(6):9174-9188. PubMed ID: 27999187
[TBL] [Abstract][Full Text] [Related]
4. Sunitinib inhibits lymphatic endothelial cell functions and lymph node metastasis in a breast cancer model through inhibition of vascular endothelial growth factor receptor 3.
Kodera Y; Katanasaka Y; Kitamura Y; Tsuda H; Nishio K; Tamura T; Koizumi F
Breast Cancer Res; 2011 Jun; 13(3):R66. PubMed ID: 21693010
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of Sphingosine Phosphate Receptor 1 Signaling Enhances the Efficacy of VEGF Receptor Inhibition.
Fischl AS; Wang X; Falcon BL; Almonte-Baldonado R; Bodenmiller D; Evans G; Stewart J; Wilson T; Hipskind P; Manro J; Uhlik MT; Chintharlapalli S; Gerald D; Alsop DC; Benjamin LE; Bhatt RS
Mol Cancer Ther; 2019 Apr; 18(4):856-867. PubMed ID: 30787172
[TBL] [Abstract][Full Text] [Related]
6. Sunitinib acts primarily on tumor endothelium rather than tumor cells to inhibit the growth of renal cell carcinoma.
Huang D; Ding Y; Li Y; Luo WM; Zhang ZF; Snider J; Vandenbeldt K; Qian CN; Teh BT
Cancer Res; 2010 Feb; 70(3):1053-62. PubMed ID: 20103629
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of Endothelial SCUBE2 (Signal Peptide-CUB-EGF Domain-Containing Protein 2), a Novel VEGFR2 (Vascular Endothelial Growth Factor Receptor 2) Coreceptor, Suppresses Tumor Angiogenesis.
Lin YC; Liu CY; Kannagi R; Yang RB
Arterioscler Thromb Vasc Biol; 2018 May; 38(5):1202-1215. PubMed ID: 29545238
[TBL] [Abstract][Full Text] [Related]
8. Anti-chloride Intracellular Channel Protein 1 (CLIC1) Antibodies Induce Tumour Necrosis and Angiogenesis Inhibition on
Radu-Cosnita AD; Nesiu A; Berzava PL; Cerbu S; Cosma A; Comsa S; Sarb S; Ferician AM; Ferician OC; Cimpean AM
Anticancer Res; 2022 Mar; 42(3):1313-1325. PubMed ID: 35220222
[TBL] [Abstract][Full Text] [Related]
9. The tyrosine kinase inhibitor cediranib blocks ligand-induced vascular endothelial growth factor receptor-3 activity and lymphangiogenesis.
Heckman CA; Holopainen T; Wirzenius M; Keskitalo S; Jeltsch M; Ylä-Herttuala S; Wedge SR; Jürgensmeier JM; Alitalo K
Cancer Res; 2008 Jun; 68(12):4754-62. PubMed ID: 18559522
[TBL] [Abstract][Full Text] [Related]
10. Neuropilin 1 and Neuropilin 2 gene invalidation or pharmacological inhibition reveals their relevance for the treatment of metastatic renal cell carcinoma.
Dumond A; Brachet E; Durivault J; Vial V; Puszko AK; Lepelletier Y; Montemagno C; Pagnuzzi-Boncompagni M; Hermine O; Garbay C; Lagarde N; Montes M; Demange L; Grépin R; Pagès G
J Exp Clin Cancer Res; 2021 Jan; 40(1):33. PubMed ID: 33461580
[TBL] [Abstract][Full Text] [Related]
11. Tumour necrosis factor superfamily member 15 (Tnfsf15) facilitates lymphangiogenesis via up-regulation of Vegfr3 gene expression in lymphatic endothelial cells.
Qin TT; Xu GC; Qi JW; Yang GL; Zhang K; Liu HL; Xu LX; Xiang R; Xiao G; Cao H; Wei Y; Zhang QZ; Li LY
J Pathol; 2015 Nov; 237(3):307-18. PubMed ID: 26096340
[TBL] [Abstract][Full Text] [Related]
12. Sunitinib Stimulates Expression of VEGFC by Tumor Cells and Promotes Lymphangiogenesis in Clear Cell Renal Cell Carcinomas.
Dufies M; Giuliano S; Ambrosetti D; Claren A; Ndiaye PD; Mastri M; Moghrabi W; Cooley LS; Ettaiche M; Chamorey E; Parola J; Vial V; Lupu-Plesu M; Bernhard JC; Ravaud A; Borchiellini D; Ferrero JM; Bikfalvi A; Ebos JM; Khabar KS; Grépin R; Pagès G
Cancer Res; 2017 Mar; 77(5):1212-1226. PubMed ID: 28087600
[TBL] [Abstract][Full Text] [Related]
13. Fucoxanthin inhibits tumour-related lymphangiogenesis and growth of breast cancer.
Wang J; Ma Y; Yang J; Jin L; Gao Z; Xue L; Hou L; Sui L; Liu J; Zou X
J Cell Mol Med; 2019 Mar; 23(3):2219-2229. PubMed ID: 30648805
[TBL] [Abstract][Full Text] [Related]
14. Suppression of Angiogenesis by Targeting Cyclin-Dependent Kinase 7 in Human Umbilical Vein Endothelial Cells and Renal Cell Carcinoma: An In Vitro and In Vivo Study.
Shi CS; Kuo KL; Chen MS; Chow PM; Liu SH; Chang YW; Lin WC; Liao SM; Hsu CH; Hsu FS; Chang HC; Huang KH
Cells; 2019 Nov; 8(11):. PubMed ID: 31752390
[TBL] [Abstract][Full Text] [Related]
15. Targeting of tumor growth and angiogenesis underlies the enhanced antitumor activity of lenvatinib in combination with everolimus.
Matsuki M; Adachi Y; Ozawa Y; Kimura T; Hoshi T; Okamoto K; Tohyama O; Mitsuhashi K; Yamaguchi A; Matsui J; Funahashi Y
Cancer Sci; 2017 Apr; 108(4):763-771. PubMed ID: 28107584
[TBL] [Abstract][Full Text] [Related]
16. Rac Signaling Drives Clear Cell Renal Carcinoma Tumor Growth by Priming the Tumor Microenvironment for an Angiogenic Switch.
Goka ET; Chaturvedi P; Lopez DTM; Lippman ME
Mol Cancer Ther; 2020 Jul; 19(7):1462-1473. PubMed ID: 32371578
[TBL] [Abstract][Full Text] [Related]
17. Acceleration of clear cell renal cell carcinoma growth in mice following bevacizumab/Avastin treatment: the role of CXCL cytokines.
Grepin R; Guyot M; Jacquin M; Durivault J; Chamorey E; Sudaka A; Serdjebi C; Lacarelle B; Scoazec JY; Negrier S; Simonnet H; Pages G
Oncogene; 2012 Mar; 31(13):1683-94. PubMed ID: 21909141
[TBL] [Abstract][Full Text] [Related]
18. Vascular endothelial growth factor c promotes ovarian carcinoma progression through paracrine and autocrine mechanisms.
Decio A; Taraboletti G; Patton V; Alzani R; Perego P; Fruscio R; Jürgensmeier JM; Giavazzi R; Belotti D
Am J Pathol; 2014 Apr; 184(4):1050-1061. PubMed ID: 24508126
[TBL] [Abstract][Full Text] [Related]
19. The vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor cediranib (Recentin; AZD2171) inhibits endothelial cell function and growth of human renal tumor xenografts.
Siemann DW; Brazelle WD; Jürgensmeier JM
Int J Radiat Oncol Biol Phys; 2009 Mar; 73(3):897-903. PubMed ID: 19215823
[TBL] [Abstract][Full Text] [Related]
20. Vascular disruption in combination with mTOR inhibition in renal cell carcinoma.
Ellis L; Shah P; Hammers H; Lehet K; Sotomayor P; Azabdaftari G; Seshadri M; Pili R
Mol Cancer Ther; 2012 Feb; 11(2):383-92. PubMed ID: 22084164
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
